Children's Oncology Group and Apeiron to jointly conduct phase II study in neuroblastoma with APN301
05-Oct-2011 -
APEIRON Biologics AG and the Children s Oncology Group (COG) announced a collaboration on conducting a clinical phase II study in neuroblastoma patients.
In the course of this new clinical trial, Apeiron´s APN301, a recombinant fusion protein consisting of the humanized anti-GD2 monoclonal ...
cancer
monoclonal antibodies
neuroblastoma